AgingResearch.NewsJoin free

N201-GAL

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Ministry of Science and ICT, South Korea and 3 more
  • Animals1

Outcomes

2

Visual function

upin mice1

1 study

  1. N201-GAL improves visual function in mice.

    “significantly restored retinal tissue integrity and visual function through the targeted clearance of senescent cells”

    Animalsdoxorubicin-induced retinal senescence model

    A Self-Assembling Senolytic Prodrug with Enhanced Bioavailability and Selective Activation for Targeting Senescent Retinal Pigment Epithelium

    Biomaterials research1 Oct 2025

Retinal tissue integrity

upin mice1

1 study

  1. N201-GAL improves retinal tissue integrity in mice.

    “oral administration of N201-gal in a mouse model of doxorubicin-induced retinal senescence model significantly restored retinal tissue integrity”

    Animalsdoxorubicin-induced retinal senescence modelretina

    A Self-Assembling Senolytic Prodrug with Enhanced Bioavailability and Selective Activation for Targeting Senescent Retinal Pigment Epithelium

    Biomaterials research1 Oct 2025

Latest

Related